natgillin/translations-raw huggingface dataset:
PDE- 5- hæmmere Sildenafil Vardenafil Tadalafil Rifamyciner
PDE-5 inhibitors Sildenafil Vardenafil Tadalafil Rifamycines
I et interaktionsforsøg blev der observeret en tilsvarende systemisk eksponering for sildenafil ved en enkeltdosis sildenafil på 100 mg alene og en enkeltdosis sildenafil på 25 mg, co- administreret med darunavir/ ritonavir (400/ 100 mg x 2).
In an interaction study a comparable systemic exposure to sildenafil was observed for a single intake of 100 mg sildenafil alone and a single intake of 25 mg sildenafil co-administered with darunavir/ritonavir (400/100 mg b.i.d.).
Der skal udvises forsigtighed ved samtidig brug af PDE- 5- hæmmere og PREZISTA, co- administreret med 100 mg ritonavir.
Concomitant use of PDE-5 inhibitors with PREZISTA co-administered with 100 mg ritonavir should be done with caution.
Hvis samtidig brug af PREZISTA, co- administreret med 100 mg ritonavir, og sildenafil, vardenafil eller tadalafil er indiceret, anbefales det at give en enkeltdosis sildenafil på højst 25 mg i løbet af 48 timer, en enkeltdosis vardenafil på højst 2, 5 mg i løbet af 72 timer eller en enkeltdosis tadalafil på højst 10 mg i løbet af 72 timer.
If concomitant use of PREZISTA co-administered with 100 mg ritonavir with sildenafil, vardenafil, or tadalafil is indicated, sildenafil at a single dose not exceeding 25 mg in 48 hours, vardenafil at a single dose not exceeding 2.5 mg dose in 72 hours or tadalafil at a single dose not exceeding 10 mg dose in 72 hours is recommended.
Rifampicin
9 Rifampicin
Dette kan resultere i tab af virologisk respons og resistensudvikling.
Rifampicin is a strong CYP3A4 inducer and has been shown to cause profound decreases in concentrations of other protease inhibitors, which can result in virological failure and resistance development.
4. 3).
Rifabutin
Rifabutin Sedativa/ hypnotika
Rifabutin* 1.6 times ↑
150 x 1 hver anden 600/ 100 x 2 Rifabutin * 1, 6 ND dag gange ↑ Darunavir ↑ 53% ↑ 68% * totale aktive rifabutinmoieteter (rifabutin + 25- O- desacetyl- metabolit) For patienter, der får kombinationsbehandling, er der påkrævet dosisreduktion af rifabutin til 75% af den sædvanlige dosis på 300 mg/ dag [fx rifabutin 150 mg x 1 hver anden dag] samt en skærpelse i overvågningen af rifabutinrelateredebivirkninger.
(once every other day)] and increased monitoring for rifabutin related adverse events is warranted in patients receiving the combination.
I tilfælde af sikkerhedmæssige risici skal det overvejes at forlænge doseringsintervallet yderligere og/ eller monitorere rifabutinniveauerne.
In case of safety issues, a further increase of the dosing interval for rifabutin and/or monitoring of rifabutin levels should be considered.
Der skal tages højde for de officielle retningslinjer for korrekt behandling af tuberkulose hos HIV- inficerede patienter.
Consideration should be given to official guidance on the appropriate treatment of tuberculosis in HIV infected patients.
Rifabutin er en inducer af og substrat for CYP450.
Rifabutin is an inducer and substrate of CYP3A4.
Der er observeret en øget systemisk eksponering af darunavir ved samtidig brug af PREZISTA, co- administreret med 100 mg ritonavir sammen med rifabutin (150 mg x 1 hver anden dag).
An increase of systemic exposure to darunavir was observed when PREZISTA co-administered with 100 mg ritonavir was co-administered with rifabutin [150 mg q.o.d.
På baggrund af sikkerhedsprofilen for PREZISTA/ ritonavir giver denne øgede eksponering af darunavir ved samtidig administration af rifabutin ikke anledning til en justering af dosis for PREZISTA/ ritonavir.
Based upon the safety profile of PREZISTA/ritonavir, this increase in darunavir exposure in the presence of rifabutin does not warrant a dose adjustment for PREZISTA/ritonavir.
Interaktionsforsøget viste en sammenlignelig daglig systemisk eksponering af rifabutin imellem behandling med 300 mg x 1 og 150 mg x 1 hver anden dag i kombination med PREZISTA/ ritonavir (600/ 100 x 2).
The interaction trial showed a comparable daily systemic exposure for rifabutin between treatment at 300 mg q.d.
Forsøget viste samtidig en ca.
(once daily) alone and 150 mg q.o.d.
10 gange forøgelse af den daglige eksponering af den aktive metabolit 25- O - desacetylrifabutin.
(once every other day) in combination with PREZISTA/ritonavir (600/100 mg b.i.d.) with an about 10-fold increase in the daily exposure to the active metabolite 25-O-desacetylrifabutin.
Desuden blev AUC for totale aktive rifabutinmoieteter (lægemiddelstof + 25- O- desacetyl metabolit) forøget 1, 6 gange, mens Cmax forblev sammenlignelig.
Furthermore, AUC of the sum of active moieties of rifabutin (parent drug + 25-O-desacetyl metabolite) was increased 1.6-fold, while Cmax remained comparable.
Der mangler data på sammenligning med en referencedosis på 150 mg x 1.
(once daily) reference dose is lacking.
Parenteral midazolam
Sedatives/Hypnotics Parenteral midazolam
Midazolam metaboliseres i vid udstrækning af CYP3A4.
Midazolam is extensively metabolised by CYP3A4.
Co- administration af PREZISTA/ ritonavir kan give anledning til en stor forøgelse i koncentrationen af dette benzodiazepin.
Co-administration with PREZISTA/ritonavir may cause a large increase in the concentration of this benzodiazepine.
Der er ikke udført lægemiddelinteraktionsstudier for co- administration af PREZISTA/ ritonavir med benzodiazepiner.
No drug interaction study has been performed for the co-administration of PREZISTA/ritonavir with benzodiazepines.
På baggrund af data for andre CYP3A4 - hæmmere forventes midazolams plasmakoncentration at blive signifikant højere, når midazolam gives peroralt.
Based on data for other CYP3A4 inhibitors, plasma concentrations of midazolam are expected to be significantly higher when midazolam is given orally.
Der skal udvises forsigtighed ved co - administration af PREZISTA/ ritonavir og parenteral midazolam.
Therefore PREZISTA/ritonavir should not be co-administered with orally administered midazolam (see section 4.3), whereas caution should be used with co-administration of PREZISTA/ritonavir and parenteral midazolam.
Data for samtidig brug af parenteral midazolam med andre proteasehæmmere peger på en mulig 3- 4- dobbelt forøgelse af midazolams plasmaniveau.
Data from concomitant use of parenteral midazolam with other protease inhibitors suggest a possible 3-4 fold increase in midazolam plasma levels.
Hvis PREZISTA/ ritonavir co- administreres med parenteral midazolam, skal det foregå på en intensiv afdeling eller i lignende rammer, der sikrer en tæt klinisk monitorering og passende medicinsk håndtering i tilfælde af respirationsdepression og/ eller forlænget sedation.
If PREZISTA/ritonavir is co-administered with parenteral midazolam, it should be done in an intensive care unit (ICU) or similar setting, which ensures close clinical monitoring and appropriate medical management in case of respiratory depression and/or prolonged sedation.
Det bør overvejes at justere dosis af midazolam, især hvis der administreres mere end en enkelt dosis midazolam.
Dosage adjustment for midazolam should be considered, especially if more than a single dose of midazolam is administered.
10 Selektive serotonin genoptagshæmmere (SSRI’ er) Paroxetin
Selective Serotonin Reuptake Inhibitors (SSRIs) Paroxetine
400/ 100 x 2 #
400/100
Paroxetin 20 x 1 400/ 100 x 2 # Paroxetin
400/100 b.i.d.# Paroxetine
↓ 39%
↓ 39%
50 x 1
50 q.d.
400/ 100 x 2 #
Sertraline 50 q.d.
Sertralin Darunavir
400/100 b.i.d.# Sertraline
49% ↔
↓ 49%
Hvis SSRI’ er co- administreres med PREZISTA og ritonavir, er den anbefalede fremgangsmåde en forsigtig dosistitrering af SSRI’ en på grundlag af en klinisk vurdering af responset på det antidepressive middel.
If SSRIs are co-administered with PREZISTA and ritonavir, the recommended approach is a dose titration of the SSRI based on a clinical assessment of antidepressant response.
Derudover skal patienter, som får en stabil dosis sertralin eller paroxetin, og som påbegynder behandling med PREZISTA co- administreret med 100 mg ritonavir, monitoreres for respons på det antidepressive middel.
Steroids
Steroider Fluticason - propionat Budesonid
10 Fluticasone propionate Budesonide
86% (90% konfidensinterval 82- 89%).
In a clinical study where ritonavir 100 mg capsules b.i.d were co-administered with 50 µg intranasal fluticasone propionate (4 times daily) for 7 days in healthy subjects, fluticasone propionate plasma concentrations increased significantly, whereas the intrinsic cortisol levels decreased by approximately 86% (90% confidence interval 82-89%).
Der kan forventes en større effekt, kraftigere virkning, når fluticasonpropionat inhaleres.
Greater effects may be expected when fluticasone propionate is inhaled.
Dette kan også forekomme med andre kortikosteroider, der metaboliseres via P450 3A såsom budesonid.
Systemic corticosteroid effects including Cushing's syndrome and adrenal suppression have been reported in patients receiving ritonavir and inhaled or intranasally administered fluticasone propionate; this could also occur with other corticosteroids metabolised via the P450 3A pathway e.g. budesonide.
Derfor anbefaler man ikke samtidig administration af PREZISTA co- administreret med 100 mg ritonavir og disse glukokortikoider, medmindre den mulige fordel ved behandlingen opvejer risikoen ved systemiske kortikosteroideffektervirkninger.
Consequently, concomitant administration of PREZISTA, co-administered with 100 mg ritonavir and these glucocorticoids, is not recommended unless the potential benefit of treatment outweighs the risk of systemic corticosteroid effects.
En dosisreduktion af glukokortikoid bør overvejes med grundig monitorering af lokale og systemiske effekter eller et skift til et glukokortikoid, der ikke er et substrat af CYP3A4 (f. eks. beclomethason).
A dose reduction of the glucocorticoid should be considered with close monitoring of local and systemic effects or a switch to a glucocorticoid, which is not a substrate for CYP3A4 (e.g. beclomethasone).
I tilfælde af seponering af glukokortikoider skal detter måske muligvis foretages som en progressiv dosisaftrapningreduktion over en længere periode.
Moreover, in case of withdrawal of glucocorticoids progressive dose reduction may have to be performed over a longer period.
Virkningerne af høj systemisk eksponering for fluticason på plasmaniveauerne af ritonavir kendes endnu ikke.
The effects of high fluticasone systemic exposure on ritonavir plasma levels are as yet unknown.
Dexamethason Andre
Dexamethasone Others
Systemisk dexamethason inducerer CYP3A4 og kan derved øge niveauet af darunavir.
Systemic dexamethasone induces CYP3A4 and thereby may decrease darunavir exposure.
Der skal derfor udvises forsigtighed ved brug af denne kombination.
Therefore this combination should be used with caution.
Perikon
John’s wort
PREZISTA, co- administreret med 100 mg ritonavir, må ikke anvendes samtidig med produkter, der indeholder perikon (Hypericum perforatum), da co- administration kan forårsage signifikante fald i plasmakoncentrationen af darunavir og i koncentrationen af ritonavir.
PREZISTA co-administered with 100 mg ritonavir must not be used concomitantly with products containing St John’s wort (Hypericum perforatum) because co-administration may cause significant decreases in darunavir plasma concentrations and also in ritonavir concentrations.
Dette skyldes perikons inducering af metaboliseringsenzymer.
This is due to the induction of metabolising enzymes by St John’s wort.
Hvis en patient allerede tager perikon, bør man seponere perikon og, om muligt, måle det virale niveau.
If a patient is already taking St John’s wort, stop St John’s wort and if possible check viral levels.
Graviditet Der er ikke udført tilstrækkelige og velkontrollerede forsøg med darunavir hos gravide kvinder.
Pregnancy There are no adequate and well controlled studies with darunavir in pregnant women.
5. 3).
Studies in animals do not indicate direct harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development (see section 5.3).
PREZISTA, co- administreret med 100 mg ritonavir, bør kun anvendes under graviditet, hvis den mulige fordel opvejer den mulige risiko.
PREZISTA co-administered with 100 mg ritonavir should be used during pregnancy only if the potential benefit justifies the potential risk.
Amning Det vides ikke, om darunavir udskilles i brystmælk hos mennesker.
Lactation It is not known whether darunavir is excreted in human milk.
Forsøg med rotter har vist, at darunavir udskilles i mælk og medførte toksicitet ved høje niveauer (1. 000 mg/ kg/ dag).
Studies in rats have demonstrated that darunavir is excreted in milk and at high levels (1,000 mg/kg/day) resulted in toxicity.
Både på grund af risiko for overførsel af HIV og risiko for uønskede hændelser hos de ammende spædbørn, skal mødre instrueres i, at de under ingen omstændigheder må amme, hvis de behandles med PREZISTA.
Because of both the potential for HIV transmission and the potential for adverse events in nursing infants, mothers should be instructed not to breast-feed under any circumstances if they are receiving PREZISTA.
11 Der foreligger ingen data om virkningen af darunavir på fertilitet hos mennesker.
Fertility No human data on the effect of darunavir on fertility are available.
5. 3).
There was no effect on mating or fertility with darunavir treatment in rats (see section 5.3).
Der er ikke foretaget undersøgelser af virkningen af PREZISTA i kombination med ritonavir på evnen til at føre motorkøretøj og betjene maskiner.
No studies on the effects of PREZISTA in combination with ritonavir on the ability to drive and use machines have been performed.
4. 8).
However, dizziness has been reported in some patients during treatment with regimens containing PREZISTA co-administered with 100 mg ritonavir and should be borne in mind when considering a patient’s ability to drive or operate machinery (see section 4.8).
Medianeksponeringen for PREZISTA/ ritonavir hos denne gruppe patienter var 37, 3 uger.
The adverse drug reactions are derived from Phase IIb and Phase III trials, in which a total of 1,968 treatment-experienced patients initiated therapy with the recommended dose of PREZISTA 600 mg 11 with ritonavir 100 mg twice daily.Median exposure to PREZISTA/ritonavir in this group was 37.3 weeks.
30% af disse patienterne oplevede mindst én bivirkning med en sværhedsgrad på mindst 2.
Thirty percent of these patients experienced at least one adverse drug reaction of at least grade 2 severity.
De mest hyppige (≥2%) af disse rapporterede uønskede reaktioner var: diarré (3, 9%), hypertriglyceridæmi (3, 8%), udslæt (2, 8%), kvalme (2, 6%), hyperkolesterolæmi (2, 5%) og hovedpine (2, 0%).
The most frequent (≥ 2%) of those were diarrhoea (3.9%), hypertriglyceridaemia (3.8%), rash (2.8%), nausea (2.6%), hypercholesterolaemia (2.5%) and headache (2.0%).
2, 6% af patienterne afbrød behandlingen på grund af uønskede reaktioner.
2.6% of the patients discontinued treatment due to adverse reactions.
Bivirkningerne er opstillet efter organklasse (SOC) og hyppighed.
Adverse reactions are listed by system organ class (SOC) and frequency.
Inden for hver hyppighedsgruppe er bivirkningerne vist efter aftagende alvorlighed.
Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.
Hyppigheder defineres som meget almindelig (≥ 1/ 10), almindelig (≥ 1/ 100 til < 1/ 10) og ikke almindelig (≥ 1/ 1. 000 til < 1/ 100).
Frequencies are defined as very common (≥ 1/10), common (≥ 1/100 to < 1/10) and uncommon (≥ 1/1,000 to < 1/100).
SOC Hyppighedskategori
SOC Frequency category
Bivirkninger Alle sværhedsgrader
Adverse reaction* All grades
Bivirkninger Sværhedsgrad 2- 4
Adverse reaction** Grade 2-4
Infektioner og parasitære
Infections and infestations uncommon
ikke almindelig
Blood and lymphatic system disorders uncommon
trombocytopeni, neutropeni, anæmi, forøget eosinofiltal, leukopeni
thrombocytopenia, neutropenia, anaemia, increased eosinophil count, leukopenia
trombocytopeni, neutropeni, anæmi
thrombocytopenia, neutropenia, anaemia
Immunsystemet ikke almindelig
Immune system disorders uncommon Endocrine disorders
immunrekonstitutionssyndrom
immune reconstitution syndrome
hypothyroidisme, forøget thyroidstimulerende hormon i blodet
hypothyroidism, increased blood thyroid stimulating hormone
Metabolisme og ernæring almindelig
Metabolism and nutrition disorders common
lipodystrofi (inklusive lipohypertrofi, lipodystrofi og lipoatrofi), hypertriglyceridæmi, hyperkolesterolæmi, hyperlipidæmi
lipodystrophy (including lipohypertrophy, lipodystrophy, lipoatrophy), hypertriglyceridaemia, hypercholesterolaemia, hyperlipidaemia
hypertriglyceridæmi, hyperkolesterolæmi, hyperlipidæmi
hypertriglyceridaemia, hypercholesterolaemia, hyperlipidaemia
diabetes mellitus, arthritis urica, anoreksi, nedsat appetit, vægttab, vægtstigning, hyperglykæmi, insulinresistens, nedsat HDL, øget appetit, polydipsi, øget lactase - dehydrogenase i blodet
diabetes mellitus, gout, anorexia, decreased appetite, decreased weight, increased weight, hyperglycaemia, insulin resistance, decreased high density lipoprotein, increased appetite, polydipsia, increased blood lactate dehydrogenase
diabetes mellitus, lipodystrofi (inklusive lipohypertrofi, lipodystrofi og lipoatrofi), arthritis urica, anoreksi, nedsat appetit, vægttab, vægtstigning, hyperglykæmi, insulinresistens
diabetes mellitus, lipodystrophy (including lipohypertrophy, lipodystrophy, lipoatrophy), gout, anorexia, decreased appetite, decreased weight, increased weight, hyperglycaemia, insulin resistance
12 Psykiske forstyrrelser almindelig
Psychiatric disorders common
søvnløshed
insomnia
ikke almindelig Nervesystemet
uncommon
depression, konfusion, desorientering, angst, humørændring, søvnforstyrrelser, unormale drømme, mareridt, nedsat libido, rastløshed
depression, confusional state, disorientation, anxiety, altered mood, sleep disorder, abnormal dreams, nightmare, decreased libido, restlessness
depression, konfusion, desorientering, angst, humørændring, søvnløshed, søvnforstyrrelser, unormale drømme
depression, confusional state, disorientation, anxiety, altered mood, insomnia, sleep disorder, abnormal dreams
almindelig
Nervous system disorders common
ikke almindelig Øjne
uncommon Eye disorders
besvimelse, krampe, lethargi, paræstesi, hypæstesi, ageusi, dysageusi, opmærksomhedsforstyrrelser, hukommelsestab, somnolens, forstyrrelser i søvnfaserytmen
syncope, convulsion, lethargy, paraesthesia, hypoaesthesia, ageusia, dysgeusia, disturbance in attention, memory impairment, somnolence, sleep phase rhythm disturbance
perifer neuropati, svimmelhed, lethargi, paræstesi, hypæstesi, somnolens
peripheral neuropathy, dizziness, lethargy, paraesthesia, hypoaesthesia, somnolence
ikke almindelig Øre og labyrint
12 uncommon
synsforstyrrelser, konjunktival hyperæmi, tørre øjne
visual disturbance, conjunctival hyperaemia, dry eye
ikke almindelig Hjerte
Ear and labyrinth disorders uncommon Cardiac disorders
ikke almindelig Vaskulære sygdomme
un common Vascular disorders
akut myokardieinfarkt, myokardieinfarkt, angina pectoris, elektrokardiogram, der viser QT - forlængelse, sinus bradykardi, takykardi, hjertebanken
acute myocardial infarction, myocardial infarction, angina pectoris, prolonged electrocardiogram QT, sinus bradycardia, tachycardia, palpitations
akut myokardieinfarkt, myokardieinfarkt, angina pectoris, elektrokardiogram, der viser QT - forlængelse
acute myocardial infarction, myocardial infarction, angina pectoris, prolonged electrocardiogram QT
Hypertension, rødmen
hypertension, flushing
hypertension
hypertension
Luftveje, thorax og mediastinum ikke almindelig Mave- tarm- kanalen
Respiratory, thoracic and mediastinal disorders uncommon
dyspnø, hoste, næseblødning, næseflåd, halsirritation
dyspnoea, cough, epistaxis, rhinorrhoea, throat irritation
meget almindelig
Gastrointestinal disorders very common
opkastning, kvalme, abdominale smerter, forhøjet blodamylase, dyspepsi, abdominal distention, flatulens
vomiting, nausea, abdominal pain, increased blood amylase, dyspepsia, abdominal distension, flatulence
opkastning, diarré, kvalme, abdominale smerter, forhøjet blodamylase
vomiting, diarrhoea, nausea, abdominal pain, increased blood amylase
ikke almindelig Lever og galdeveje
uncommon
pankreatitis, gastritis, gastroøsofageal reflukssygdom, aftøs stomatitis, stomatitis, opkastningsfornemmelser, hæmatemese, mundtørhed, mavebesvær, forstoppelse, forhøjet lipase, ræben, oral dysæstesi, keilit, tørre læber, belægninger på tungen
pancreatitis, gastritis, gastrooesophageal reflux disease, aphthous stomatitis, stomatitis, retching, haematemesis, dry mouth, abdominal discomfort, constipation, increased lipase, eructation, oral dysaesthesia, cheilitis, dry lip, coated tongue
pankreatitis, gastritis, gastroøsofageal reflukssygdom, aftøs stomatitis, opkastningsfornemmelser, mundtørhed, abdominal distention, mavebesvær, flatulens, dyspepsi, forstoppelse, forhøjet lipase
pancreatitis, gastritis, gastrooesophageal reflux disease, aphthous stomatitis, retching, dry mouth, abdominal distension, abdominal discomfort, flatulence, dyspepsia, constipation, increased lipase
almindelig
Hepatobiliary disorders common
forhøjet alanin- aminotranferase, forhøjet aspartat- aminotranferase
increased alanine aminotransferase, increased aspartate aminotransferase
forhøjet alanin- aminotranferase
increased alanine aminotransferase
13 ikke almindelig Hud og subkutane væv
uncommon
hepatitis, cytolytisk hepatitis, hepatisk steatose, hepatomegali, forhøjet transaminase, forhøjet bilirubin i blodet, forhøjet alkalisk fosfatase, forhøjet gamma - glutamyltransferase
hepatitis, cytolytic hepatitis, hepatic steatosis, hepatomegaly, increased transaminase, increased blood bilirubin, increased blood alkaline phosphatase, increased gamma-glutamyltransferase
hepatitis, cytolytisk hepatitis, hepatisk steatose, forhøjet transaminase, forhøjet aspartat - aminotranferase, forhøjet alkalisk fosfatase, forhøjet gamma - glutamyltransferase
hepatitis, cytolytic hepatitis, hepatic steatosis, increased transaminase, increased aspartate aminotransferase, increased blood alkaline phosphatase, increased gamma-glutamyltransferase
almindelig
Skin and subcutaneous tissue disorders common
udslæt (herunder makuløst, makulopapuløst, papuløst, erytematøst og kløende udslæt)
rash (including macular, maculopapular, papular, erythematous and pruritic rash)
generaliseret udslæt, allergisk dermatitis, faciale ødemer, nældefeber, dermatitis, eksem, erytem, hyperhidrose, nattesved, alopeci, akne, seboroisk dermatitis, hudlæssioner, xeroderma, tør hud, neglepigmentering
generalised rash, allergic dermatitis, face oedema, urticaria, dermatitis, eczema, erythema, hyperhidrosis, night sweats, alopecia, acne, seborrhoeic dermatitis, skin lesion, xeroderma, dry skin, nail pigmentation
generaliseret udslæt, allergisk dermatitis, nældefeber, kløe, hyperhidrose, nattesved, alopeci
generalised rash, allergic dermatitis, urticaria, pruritus, hyperhidrosis, night sweats, alopecia
ikke almindelig Nyrer og urinveje
Musculoskeletal and connective tissue disorders uncommon
myalgi, muskelspasmer, muskelsvaghed, stivhed i skeletmuskulaturen, artrit, artralgi, ledstivhed, smerter i ekstremiteter, osteoporose, forhøjet kreatininfosfokinase i blodet
myalgia, muscle spasms, muscular weakness, musculoskeletal stiffness, arthritis, arthralgia, joint stiffness, pain in extremity, osteoporosis, increased blood creatine phosphokinase
myalgi, artralgi, smerter i ekstremiteter, osteoporose, forhøjet kreatininfosfokinase i blodet
myalgia, arthralgia, pain in extremity, osteoporosis, increased blood creatine phosphokinase
ikke almindelig
Renal and urinary disorders uncommon
akut nyresvigt, nyresvigt, nephrolitiasis, forhøjet kreatinin i blodet, nedsat kreatininclearance i nyrerne, proteinuri, bilirubinuri, dysuri, nocturi, pollakisuri
acute renal failure, renal failure, nephrolithiasis, increased blood creatinine, decreased creatinine renal clearance, proteinuria, bilirubinuria, dysuria, nocturia, pollakiuria